159 related articles for article (PubMed ID: 21080395)
1. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
Klüter S; Simard JR; Rode HB; Grütter C; Pawar V; Raaijmakers HC; Barf TA; Rabiller M; van Otterlo WA; Rauh D
Chembiochem; 2010 Dec; 11(18):2557-66. PubMed ID: 21080395
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
[TBL] [Abstract][Full Text] [Related]
4. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.
Yu Z; Boggon TJ; Kobayashi S; Jin C; Ma PC; Dowlati A; Kern JA; Tenen DG; Halmos B
Cancer Res; 2007 Nov; 67(21):10417-27. PubMed ID: 17974985
[TBL] [Abstract][Full Text] [Related]
5. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
Barchéchath S; Williams C; Saade K; Lauwagie S; Jean-Claude B
Chem Biol Drug Des; 2009 Apr; 73(4):380-7. PubMed ID: 19291100
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.
Pawar VG; Sos ML; Rode HB; Rabiller M; Heynck S; van Otterlo WA; Thomas RK; Rauh D
J Med Chem; 2010 Apr; 53(7):2892-901. PubMed ID: 20222733
[TBL] [Abstract][Full Text] [Related]
7. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.
Hegymegi-Barakonyi B; Eros D; Szántai-Kis C; Breza N; Bánhegyi P; Szabó GV; Várkondi E; Peták I; Orfi L; Kéri G
Curr Opin Mol Ther; 2009 Jun; 11(3):308-21. PubMed ID: 19479664
[TBL] [Abstract][Full Text] [Related]
10. Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization.
Tasler S; Müller O; Wieber T; Herz T; Pegoraro S; Saeb W; Lang M; Krauss R; Totzke F; Zirrgiebel U; Ehlert JE; Kubbutat MH; Schächtele C
Bioorg Med Chem; 2009 Sep; 17(18):6728-37. PubMed ID: 19692247
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Guo M; Dai S; Wu D; Duan Y; Li J; Qu L; Jiang L; Chen Z; Chen X; Chen Y
Bioorg Med Chem Lett; 2021 Feb; 34():127757. PubMed ID: 33359446
[TBL] [Abstract][Full Text] [Related]
12. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.
Blair JA; Rauh D; Kung C; Yun CH; Fan QW; Rode H; Zhang C; Eck MJ; Weiss WA; Shokat KM
Nat Chem Biol; 2007 Apr; 3(4):229-38. PubMed ID: 17334377
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species.
Meng D; Shi X; Jiang BH; Fang J
Free Radic Biol Med; 2007 Jun; 42(11):1651-60. PubMed ID: 17462533
[TBL] [Abstract][Full Text] [Related]
15. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.
Zhang X; Gureasko J; Shen K; Cole PA; Kuriyan J
Cell; 2006 Jun; 125(6):1137-49. PubMed ID: 16777603
[TBL] [Abstract][Full Text] [Related]
16. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
17. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
18. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Liu W; Wu X; Zhang W; Montenegro RC; Fackenthal DL; Spitz JA; Huff LM; Innocenti F; Das S; Cook EH; Cox NJ; Bates SE; Ratain MJ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6788-95. PubMed ID: 18006781
[TBL] [Abstract][Full Text] [Related]
19. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
[TBL] [Abstract][Full Text] [Related]
20. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
